Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 394-403

  Fetherston, Susan M ^a   Geer, Leslie ^b   Veazey, Ronald S ^c   Goldman, Laurie ^b   Murphy, Diarmaid J ^a   Ketas, Thomas J ^d   Klasse, Per Johan ^d   Blois, Sylvain ^e   La colla, Paolo ^e   Moore, John P ^d   Malcolm, R Karl ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Particle Sciences   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

HIV 1 microbicide; Pharmacokinetics; Rhesus macaque; RT SHIV challenge; Silicone elastomer vaginal ring

Indexed keywords

2 PROPANOL; MC 1220; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; SILASTIC; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HAZARD RATIO; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RHESUS MONKEY; SILICONE ELASTOMER VAGINAL RING; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SIMULATED VAGINAL FLUID; TREATMENT DURATION; VAGINA; VAGINA DISCHARGE; VAGINA RING; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BODY FLUIDS; CONTRACEPTIVE DEVICES, FEMALE; DRUG CARRIERS; FEMALE; HUMANS; MACACA MULATTA; PLASMA; PYRIMIDINONES; SILICONE ELASTOMERS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VAGINA;

EID: 84872396180     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks415     Document Type: Article

References (38)

1. Malcolm RK, Woolfson AD, Toner CF et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 954-6.
2. Woolfson AD, Malcolm RK, Toner CF et al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV a controlled-release strategy for HIV microbicides. Am J Drug Deliv 2006; 4: 7-20.
3. Nel A, Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-23.
4. Romano R, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Human Retrovir 2009; 25: 483-8.
5. Johnson TJ, Gupta KM, Fabian J et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39: 203-12.
6. Malcolm RK, Edwards K-L, Kiser P et al. Advances in microbicide vaginal rings. Antivir Res 2010; 88: S30-9.
7. Johnson TF, Srinivasan P, Albright TH et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012; 56: 1291-9.
8. Malcolm RK, Veazey RS, Geer L et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56: 2251-8.
9. Mesquita PMM, Rastogi R, Segarra TJ et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 2012; 67: 1730-8..
10. Veazey RS. Microbicide safety/efficacy studies in animals-macaques and small animal models. Curr Opin HIV AIDS 2008; 3: 567-73.
11. Veazey RS, Shattock RJ, Klasse PJ et al. Animal models for microbicide studies. Curr HIV Res 2012; 10: 79-87.
12. Promadej-Lanier N, Smith JM, Srinivasan P et al. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J Med Primatol 2009; 38: 263-71.
13. Pal R, Galmin L, Pereira LE et al. Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. Virology 2012; 432: 173-83.
14. Caron M, Besson G, Etenna SLD et al. Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of rhesus macaques with RT-SHIV. Virology 2010; 405: 225-33.
15. Stolte-Leeb N, Loddo R, Antimisiaris S et al. Topical nonnucleoside reverse transcriptase inhibitor MC1220 partially prevents vaginal RT-SHIV infection of macaques. AIDS Res Human Retrovir 2011; 27: 933-43.
16. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91-5.
17. Ketas TJ, Holuigue S, Matthews K et al. Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology 2012; 422: 22-36.
18. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 1-2.
19. Forbes CJ, Lowry D, Geer L et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Rel 2011; 156: 161-9.
20. Smith JM, Dauner A, Li B et al. Generation of a dual RT Env SHIV that is infectious in rhesus macaques. J Med Primatol 2010; 39: 213-23.
21. Gramaglia D, Conway BR, Kett VL et al. High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. Int J Pharm 2005; 301: 1-5.
22. McBride M, Boyd P, Fetherston S et al. Preclinical stability evaluation of vaginal rings containing dapivirine and maraviroc. In: Abstracts of the Microbicides 2010 Conference, Pittsburgh, PA, 2010. Abstract 250, p. 173.
23. Fetherston S, Boyd P, McBride M et al. Preclinical stability evaluation of dapivirine and maraviroc release in vitro from combination silicone elastomer vaginal rings. In: Abstracts of the 37th Annual Meeting & Exposition of the Controlled Release Society, Portland, OR, 2010. Abstract 838, p. 58. Controlled Release Society, St Paul, MN, USA.
24. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Therapeut 1957; 119: 361-9.
25. Spear GT, Gilbert D, Sikaroodi M et al. Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res Hum Retrovir 2010; 26: 193-200.
26. Smith KPB. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol releasing vaginal ring. Acta Obstet Gynecol Scand 1993; 72 Suppl 157: S1-26.
27. Moss JA, Malone AM, Smith TJ et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother 2012; 56: 875-82.
28. Schwartz JL, Rountree W, Kashuba ADM et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS ONE 2011; 6: e25974.
29. Nuttall J, Kashuba A, Wang R et al. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 2012; 56: 103-9.
30. Abdool Karim SS, Kashuba ADM, Werner L et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378: 279-81.
31. Barouch DH, Klasse PJ, Dufour J et al. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012; 109: 8694-8.
32. Letvin NL, Rao SS, Montefiori DC et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3: 81ra36.
33. Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482: 89-93.
34. Lai L, Kwa SF, Kozlowski PA et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012; 30: 1737-45.
35. Xiao P, Patterson LJ, Kuate S et al. Replicating adenovirus-SIV recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low dose rectal SIVmac251 challenge. J Virol 2012; 86: 4644-57.
36. Bell SE, Dennis AC, Fido LA et al. Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. J Pharm Pharmacol 2007; 59: 203-7.
37. Morrow RJ, Woolfson AD, Donnelly L et al. Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm 2011; 77: 3-10.
38. Pattani A, Lowry D, Curran RM et al. Characterisation of protein stability in rod-insert vaginal rings. Int J Pharm 2012; 430: 89-97.